{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:34:15Z","timestamp":1793835255392,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-025-01881-9","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T22:10:47Z","timestamp":1740607847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of noninvasive fibrosis calculators in an urban diabetes center suggests a large burden of undetected advanced liver disease"],"prefix":"10.1186","volume":"25","author":[{"given":"Ahmed","family":"Ebeid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Mokhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Martinez-Lebron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seta","family":"Degann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Payano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahid","family":"Vahora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynt","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diala","family":"El-Maouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameer","family":"Abutaleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"3","key":"1881_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/MCG.0000000000000905","volume":"52","author":"A Singh","year":"2018","unstructured":"Singh A, Le P, Peerzada MM, Lopez R, Alkhouri N. The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver Disease and Advanced Fibrosis in type 2 Diabetic patients. J Clin Gastroenterol. 2018;52(3):268\u201372.","journal-title":"J Clin Gastroenterol"},{"key":"1881_CR2","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47\u201364.","journal-title":"J Hepatol"},{"key":"1881_CR3","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/hep.20466","volume":"40","author":"JD Browning","year":"2004","unstructured":"Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387\u201395.","journal-title":"Hepatology"},{"key":"1881_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1881_CR5","first-page":"6638306","volume":"2020","author":"CM Muzica","year":"2020","unstructured":"Muzica CM, Sfarti C, Trifan A, Zenovia S, Cuciureanu T, Nastasa R, Huiban L, Cojocariu C, Singeap AM, Girleanu I, et al. Nonalcoholic fatty liver disease and type 2 diabetes Mellitus: a bidirectional relationship. Can J Gastroenterol Hepatol. 2020;2020:6638306.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"1881_CR6","doi-asserted-by":"crossref","unstructured":"Forlani G, Giorda C, Manti R et al. The burden of NAFLD and its characteristics in a nationwide population with type 2 diabetes. J Diabetes Res. 2016; 2016:2931985.","DOI":"10.1155\/2016\/2931985"},{"issue":"3","key":"1881_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1586\/erc.11.15","volume":"9","author":"J Richard","year":"2011","unstructured":"Richard J, Lingvay I. Hepatic steatosis and type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther. 2011;9(3):321\u20138.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"1881_CR8","unstructured":"National Diabetes Statistics Report. 2021. Available at: https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html. Accessed 07\/26\/2024."},{"issue":"39","key":"1881_CR9","doi-asserted-by":"publisher","first-page":"e8179","DOI":"10.1097\/MD.0000000000008179","volume":"96","author":"W Dai","year":"2017","unstructured":"Dai W, Ye L, Liu A, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Med (Baltim). 2017;96(39):e8179.","journal-title":"Med (Baltim)"},{"key":"1881_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00125-007-0897-4","volume":"51","author":"G Targher","year":"2008","unstructured":"Targher G, Bertolini L, Rodella S, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative\/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51:444\u201350.","journal-title":"Diabetologia"},{"key":"1881_CR11","doi-asserted-by":"crossref","unstructured":"Younossi ZM et al. Identification of high risk NAFLD patients in endocrinology clinics. Endocr Pract. 2023;29(11):912\u2013918.","DOI":"10.1016\/j.eprac.2023.06.012"},{"issue":"1","key":"1881_CR12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12913-022-07808-7","volume":"22","author":"L Gracen","year":"2022","unstructured":"Gracen L, Hayward KL, Aikebuse M, et al. Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes. BMC Health Serv Res. 2022;22(1):487.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"1881_CR13","doi-asserted-by":"publisher","first-page":"586","DOI":"10.21037\/hbsn-22-58","volume":"11","author":"M Zoncap\u00e8","year":"2022","unstructured":"Zoncap\u00e8 M, Liguori A, Tsochatzis EA. Multi-disciplinary clinic models for the management of non-alcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2022;11(4):586\u201391.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"1881_CR14","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/j.1478-3231.2007.01592.x","volume":"27","author":"B Al Knawy","year":"2007","unstructured":"Al Knawy B, Shiffman M. Percutaneous liver biopsy in clinical practice. Liver Int. 2007;27:1166\u201373.","journal-title":"Liver Int"},{"key":"1881_CR15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330\u201344.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"1881_CR16","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","volume":"71","author":"FE M\u00f3zes","year":"2022","unstructured":"M\u00f3zes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, Fournier C, Staufer K, Stauber RE, Bugianesi E, Younes R, Gaia S, Lup\u0219or-Platon M, Petta S, Shima T, Okanoue T, Mahadeva S, Chan WK, Eddowes PJ, Hirschfield GM, Newsome PN, Wong VW, de Ledinghen V, Fan J, Shen F, Cobbold JF, Sumida Y, Okajima A, Schattenberg JM, Labenz C, Kim W, Lee MS, Wiegand J, Karlas T, Y\u0131lmaz Y, Aithal GP, Palaniyappan N, Cassinotto C, Aggarwal S, Garg H, Ooi GJ, Nakajima A, Yoneda M, Ziol M, Barget N, Geier A, Tuthill T, Brosnan MJ, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M. LITMUS investigators. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006\u201319.","journal-title":"Gut"},{"issue":"4","key":"1881_CR17","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1478-3231.2009.02192.x","volume":"30","author":"BK Kim","year":"2010","unstructured":"Kim BK. Et. Al. Validation of FIB-4 and comparsion with other simple noninvasive indices for predicting liver fiboris and cirrhosis in hepatitis B virus infected patients. Liver Int. 2010;30(4):546\u201353.","journal-title":"Liver Int"},{"issue":"8","key":"1881_CR18","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3748\/wjg.v19.i8.1219","volume":"19","author":"S Treeprasertsuk","year":"2013","unstructured":"Treeprasertsuk S, Bjornsson E, Enders F, Suwanwalaikorn S, Lindor KD. NAFLD fibrosis score: a prognostic predictor for mortality and likver complications among NAFLD patients. World J Gastroenterol. 2013;19(8):1219\u201329.","journal-title":"World J Gastroenterol"},{"key":"1881_CR19","first-page":"122","volume":"20","author":"DA Khan","year":"2008","unstructured":"Khan DA, Fatima Tuz Z, Khan FA, Mubarak A. Evaluation of diagnostic accuracy of APRI for prediction of fibrosis in hepatitis C patients. J Ayub Med Coll Abbottabad. 2008;20:122\u20136.","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"1881_CR20","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of Liver diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"issue":"3","key":"1881_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/00365521.2019.1583366","volume":"54","author":"K \u00d6nnerhag","year":"2019","unstructured":"\u00d6nnerhag K, Hartman H, Nilsson PM, Lindgren S. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD). Scand J Gastroenterol. 2019;54(3):328\u201334.","journal-title":"Scand J Gastroenterol"},{"key":"1881_CR22","unstructured":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Jenny Lee, Yasaman Vali, Jerome Boursier, Rene Spijker, Anstee QM, Bossuyt PM. Mohammad H. Zafarmand1. Journal of Hepatology, 2020."},{"key":"1881_CR23","doi-asserted-by":"publisher","first-page":"1046497","DOI":"10.3389\/fphys.2022.1046497","volume":"13","author":"J Wang","year":"2022","unstructured":"Non-invasive methods, Wang J, Qin T, Sun J, Li S, Cao L, Lu X. To evaluate liver fibrosis in patients with non-alcoholic fatty liver disease. Front Physiol. 2022;13:1046497.","journal-title":"Front Physiol"},{"key":"1881_CR24","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s12879-020-05069-5","volume":"20","author":"E Yunihastuti","year":"2020","unstructured":"Diagnostic performance of APRI, Yunihastuti E, Wicaksana B, Wiraguna A, Hidayah AJ, Amelia F, Natali V, Widhani A, Sulaiman AS, Kurniawan J. FIB-4 for confirming cirrhosis in Indonesian HIV\/HCV co-infected patients. BMC Infect Dis. 2020;20:372.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"1881_CR25","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1002\/hep4.2104","volume":"6","author":"EM Gairing","year":"2022","unstructured":"A higher FIB-4, Gairing EM, Galle SJ, Weinmann-Menke PR, Schattenberg J, Kostev JM, K., Labenz C. Index is associated with an increased incidence of renal failure in the general population. Schleicher. Hepatol Commun. 2022;6(12):3505\u201314.","journal-title":"Hepatol Commun"},{"key":"1881_CR26","first-page":"155564","volume-title":"Aggravates obesity-related whitening of brown adipose tissue via PPAR\u03b1-mediated functional interplay between mitochondria and peroxisomes","author":"X Guo","year":"2023","unstructured":"Loss of APOO (MIC26), Guo X, Hu J, He G, Jin C, Yang Y, Qin D, Li C, Huang Z, Wang F. Aggravates obesity-related whitening of brown adipose tissue via PPAR\u03b1-mediated functional interplay between mitochondria and peroxisomes. Volume 144. Metabolism: Clinical and Experimental; 2023. p. 155564."},{"issue":"2","key":"1881_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","volume":"79","author":"M Kjaergaard","year":"2023","unstructured":"Kjaergaard M, Lindvig KP, Thorhauge KH, Andersen P, Hansen JK, Kastrup N, Jensen JM, Hansen CD, Johansen S, Israelsen M, Torp N, Trelle MB, Shan S, Detlefsen S, Antonsen S, Andersen JE, Graupera I, Gin\u00e9s P, Thiele M, Krag A. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 2023;79(2):277\u201386.","journal-title":"J Hepatol"},{"issue":"39","key":"1881_CR28","doi-asserted-by":"publisher","first-page":"e8179","DOI":"10.1097\/MD.0000000000008179","volume":"96","author":"W Dai","year":"2017","unstructured":"Dai W, Ye L, Liu A, Wen SW, Deng J, Wu X, Lai Z. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Med (Baltim). 2017;96(39):e8179.","journal-title":"Med (Baltim)"},{"issue":"10","key":"1881_CR29","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104\u201312.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"1881_CR30","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/oby.23263","volume":"29","author":"D Barb","year":"2021","unstructured":"Barb D, Repetto EM, Stokes ME, Shankar SS, Cusi K. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. Obes (Silver Spring). 2021;29(11):1950\u201360.","journal-title":"Obes (Silver Spring)"},{"key":"1881_CR31","unstructured":"LD-597 AASLD. 2023 MASLD Decision Tree Digital (sm)1.8, 2023. https:\/\/www.aasld.org\/sites\/default\/files\/2024-01\/SLD-597%20AASLD%202023%20MASLD%20Decision%20Tree%20Digital%20%28sm%291.8.pdf"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01881-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-01881-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01881-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T22:10:54Z","timestamp":1740607854000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-025-01881-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1881"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-01881-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4940956\/v1","asserted-by":"object"}]},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"19 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study got approved by the George Washington Institute of Review Board with a study exempt # NCR224560.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Given the study\u2019s retrospective nature, the GW IRB approved a full HIPPA waiver form. Thus, there was no need for consent from the study subject to participate or permission to publish. We have used password-encrypted data sheets from the GW EMR systems. Only the study personnel had access to the data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}